The coordination of nutrient and energy availability with cell growth and division is essential for proper immune cell development and function. By using a chemical mutagenesis strategy in mice, we identified a pedigree that has a complete block in B cell development at the pre-B cell stage resulting from a deletion in the Fnip1 gene. Enforced expression of an immunoglobulin transgene failed to rescue B cell development. Whereas essential pre-B cell signaling molecules were activated normally in Fnip1-null pre-B cells, the metabolic regulators AMPK and mTOR were dysregulated, resulting in excessive cell growth and enhanced sensitivity to apoptosis in response to metabolic stress (pre-B cell receptor crosslinking, oncogene activation). These results indicate that Folliculin-interacting protein 1 (Fnip1) is vital for B cell development and metabolic homeostasis and reveal a metabolic checkpoint that may ensure that pre-B cells have sufficient metabolic capacity to support division, while limiting lymphomagenesis caused by deregulated growth.
SUMMARY
The coordination of nutrient and energy availability with cell growth and division is essential for proper immune cell development and function. By using a chemical mutagenesis strategy in mice, we identified a pedigree that has a complete block in B cell development at the pre-B cell stage resulting from a deletion in the Fnip1 gene. Enforced expression of an immunoglobulin transgene failed to rescue B cell development. Whereas essential pre-B cell signaling molecules were activated normally in Fnip1-null pre-B cells, the metabolic regulators AMPK and mTOR were dysregulated, resulting in excessive cell growth and enhanced sensitivity to apoptosis in response to metabolic stress (pre-B cell receptor crosslinking, oncogene activation). These results indicate that Folliculin-interacting protein 1 (Fnip1) is vital for B cell development and metabolic homeostasis and reveal a metabolic checkpoint that may ensure that pre-B cells have sufficient metabolic capacity to support division, while limiting lymphomagenesis caused by deregulated growth.
INTRODUCTION
The development of all metazoan organisms involves the strict coordination of cell growth, apoptosis, division, and differentiation. During B lymphocyte development, these processes are carefully linked to an orchestrated series of ''checkpoints'' that ensure that mature B cells can mount an immunogenic response against foreign antigens, without reacting against self. The earliest committed B cell progenitor (pro-B cell) is defined by having its immunoglobulin (Ig) genes in germline (unrearranged) configuration. The Ig heavy (IgH) chain gene segments rearrange first, and after successful in-frame V H -to-D H J H juxtaposition, the IgH chain ''m'' pairs with surrogate light chain chaperones l5 and Vpre-B and signal transducing Iga and Igb chains, as a component of the pre-B cell receptor (pre-BCR) complex on the surface of pre-B cells. The pre-BCR complex then signals pre-B cells to stop V H -to-D H J H rearrangement of the other IgH allele (a process called ''allelic exclusion''), proliferate (synergistically with IL-7 receptor stimulation), start IgL chain (k and l) gene transcription and rearrangement (V L -J L ), and mature. After in-frame IgL chain rearrangement, the IgH and IgL chains pair to form IgM on the surface of immature B cells, at which point B cells with low self-reactivity exit the BM and migrate to peripheral lymphoid tissues, where development continues (see Goodnow et al., 2005 , for review).
The importance of particular signaling proteins in pre-B cell development has been demonstrated through a series of biochemical and gene-targeting studies in mice (see Hendriks and Middendorp, 2004; Herzog et al., 2009, for review) . For example, formation of the pre-BCR results in activation of the Src family protein tyrosine kinases (Ptks) Fyn, Lyn, and Blk, which phosphorylate membrane-bound Iga and Igb on their immunoreceptor tyrosine-based activation motifs (ITAMs). This results in the recruitment and activation of the Syk Ptk, which activates the Ras-Raf signaling pathway and phosphorylates the adaptor protein SLP-65 (also known as BLNK). Phosphorylated SLP-65 then forms a signaling module that recruits and activates multiple pathways including phosphatidylinositol 3-kinase (PI3K) and the Tec family Ptks Btk and Tec, which activate PLCg1/2 and ultimately Ca 2+ flux. These events altogether lead to activation of essential transcriptional mediators including Erk, Myc (Habib et al., 2007) , IRF-4/8, Foxo1, and NF-kB (see Herzog et al., 2009; Kurosaki et al., 2010, for review) .
In this study, we utilized a phenotype-driven ''reversegenetic,'' recessive ethylnitrosourea (ENU) mutagenesis strategy in mice to discover genes involved in immune cell development and function (see Appleby and Ramsdell, 2003; Cook et al., 2006, for review) . In the course of this program, we identified a pedigree (denoted LPAB.1) that selectively lacks B cells in peripheral blood. By genome scanning, the B cell immunodeficiency phenotype was mapped to a noncoding deletion in the Fnip1 gene, which encodes for the 160 kDa protein Folliculin interacting protein-1 (Fnip1) (Baba et al., 2006) . Although the biological functions of Fnip1 and the related Fnip family member Fnip2 (Hasumi et al., 2008; Takagi et al., 2008) are unknown, both molecules interact with Folliculin and AMP kinase (Baba et al., 2006; Hasumi et al., 2008) , a highly conserved master sensor and regulator of cellular metabolism (see Towler and Hardie, 2007, for review) . In response to low energy (low ATP, high AMP), AMPK is activated by phosphorylation at threonine 172 by LKB1 kinase. Activated AMPK then stimulates ATP production by increasing glucose uptake, stimulating mitochondrial biogenesis, and increasing glycolysis and oxidative phosphorylation (by inducing expression of the PGC1a and PPAR-g transcription factors). AMPK also decreases ATP consumption by inhibiting mammalian target of rapamycin (mTOR)-driven cell growth, in part by phosphorylating and activating the mTOR inhibitor tuberous sclerosis protein 2 (TSC2) (Inoki et al., 2003) and by phosphorylating and inactivating the mTOR-positive regulatory protein Raptor (Gwinn et al., 2008) . Our studies indicate that Fnip1 maintains metabolic homeostasis in developing B cells and reveal a metabolic ''checkpoint'' during B cell development, which we hypothesize may ensure that mature B cells are adequately equipped to fuel clonal expansion and antibody production, while protecting the host against excessive growth and transformation.
RESULTS

Generation of Fnip1-Null Mice by ENU Mutagenesis
We screened G3 mice from a large-scale ENU mutagenesis project for recessive mutations leading to specific immunodeficiencies. By utilizing flow cytometry to assess the representation of immune cells in peripheral blood, we identified the LPAB.1 pedigree based on an absence of B lymphocytes ( Figure 1A ), whereas myeloid and T cells were represented normally. By mapping affected G3 animals via positional cloning strategies, the LPAB.1 mutation was localized to a 1.7 Mb interval on chromosome 11. We sequenced candidate genes and identified a 32 bp deletion in exon 9 of a putative gene (A730024A03Rik), which resulted in the generation of a premature stop codon at residue 293 ( Figure S1A available online). The product of A730024A03Rik was subsequently identified as the murine homolog of Fnip1 (Baba et al., 2006) . PCR analysis confirmed that the deletion ( Figure 1B ) tracked with the B cell immunodeficiency and immunoblotting with a-Fnip1 revealed the absence of Fnip1 protein in tissues from LPAB.1 (Fnip1 À/À ) mice ( Figure 1C ).
Fnip1
À/À mice were viable and fertile but exhibited several additional phenotypes relative to wild-type (WT) littermates, including alterations in skeletal muscle (which appeared deep red as a result of high mitochondria content), increased liver glycogen content, and hypertrophic cardiomyopathy (data not shown). Taken together, these results indicate that the lack of B cells in LPAB.1 mice maps to a deletion in the Fnip1 gene, which results in the absence of Fnip1 protein.
Fnip1 Is Expressed in Multiple Tissues
We examined the expression of Fnip1 in 25 different normal mouse tissues (Park et al., 2008) by real-time PCR. We found that Fnip1 was highly expressed in testes, kidney, skeletal muscle, liver, heart, and embryo, in addition to thymus, spleen, and bone marrow (BM) ( Figure S1B ). Fnip1 was equally expressed in FACs-sorted B lineage cells throughout B cell development, whereas Fnip2 expression sharply increased during B cell development, reaching maximal levels in immature B cells ( Figure S1C ). Although both Fnip1 and Fnip2 were expressed in thymocytes, neither showed regulated expression during T cell development ( Figure S1D ). Transfection of Flagtagged Fnip1 into the WEHI B cell line indicated that Fnip1 protein resides in the cytoplasm ( Figure S1E ), as was previously Figure 2E ). These results suggest that loss of Fnip1 results in a complete block in B cell development at the large pre-B-to-small pre-B cell transition mediated by formation of the pre-BCR ( Figure 7D ; Hardy and Hayakawa, 2001 Figure S2A ), whereas the proliferation of Rag2 À/À pro-B cells is blunted as a result of the absence of pre-BCR formation, which normally synergizes with IL-7 for maximal proliferation (Fleming and Paige, 2002) . Fnip1 À/À pre-B cells also divided equally well as WT pre-B cells in vivo, based on equivalent incorporation of BrdU after 48 hr ( Figure S2B ). Fnip1 À/À B220 + CD43 mid pre-B cells, but not B220 + CD43 hi pro-B cells, exhibited significantly decreased viability relative to WT pre-B cells ( Figure 2F ). Antibody-mediated crosslinking of Igb, which mimics pre-BCR crosslinking, induced apoptosis of Fnip1 À/À pre-B cells and failed to stimulate pre-B cell development, whereas Rag2
pro-B cells were induced to mature based on downregulation of CD43 ( Figure 2G ) and upregulation of CD25 (Kouro et al., 2001) . Relative to WT pre-B cells, Fnip1 À/À pre-B cells expressed normal mRNA levels of the antiapoptotic molecule Bcl2 and slightly decreased levels of the proapoptotic molecule Bim ( Figure S2C ) and were equally sensitive to apoptosis in response to the protein kinase inhibitor staurosporine (Figure S2D) Figure 3A ) and migrate to the periphery (Figure 3B ) despite high-level IgM expression, which potently drove B cell development and migration to the periphery in Rag2
phenotype consisting of CD62L À , B220 lo , and IgM lo and were more sensitive to apoptosis in response to anti-IgM (data not shown). These results demonstrate that Fnip1 is absolutely required for pre-BCR-mediated B cell differentiation and suggest a potential role for Fnip1 in BCR-mediated maturation and survival.
Allelic Exclusion of the Ig Heavy Chain Occurs Normally in the Absence of Fnip1
It has previously been shown that expression of a rearranged IgH chain in pro-B cells mimics pre-BCR formation, resulting in suppression of endogenous IgH chain gene rearrangement (allelic exclusion) (Nussenzweig et al., 1987 (Garcia et al., 1999) . The development of donor hematopoietic cells were analyzed $15 weeks after transplantation. As shown in Figure S6 Rag2 -/-+α-Igβ Figure S4 ). Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses revealed a large percentage of the changes involved genes controlling cell metabolism and mitochondrial biogenesis and function. In particular, we found substantial increases in the expression of AMPK-regulated ''catabolic'' genes including the transcriptional coactivators peroxisome proliferator-activated receptor gamma coactivator-1a and b (Ppargc1a [Pgc1a] and Ppargc1b [Pgc1b]), which are ''master'' regulators of fatty acid oxidation (FAO) and mitochondrial biogenesis ( Figure S4 ). This correlated with a significant increase in the expression of genes involved in fatty acid metabolism and mitochondrial function. Surprisingly, we also found increases in ''anabolic'' genes involved in cellular growth such as ribosomal S6 kinase-1 (Rps6kb1), ribosome protein L3 (Rpl3), and Rasrelated GTP binding proteins B (Rragb) and D (Rragd), which are positive regulators of mTOR activation and/or function ( Figure S4 ). We next determined whether these global changes in gene expression were reflective of the biology of Fnip1 À/À pre-B cells.
First, by utilizing real-time PCR, we confirmed significantly increased expression of essential AMPK-regulated catabolic genes including Pgc1a (Pparg coactivator 1a), Pparg (peroxisome proliferator-activated receptor g) (Narkar et al., 2008) , and 4f2hc (solute carrier family 3, member 2) (Towler and Hardie, 2007) , and the glucose transporter Glut1 (Rathmell et al., 2000) , which is the main glucose transporter in lymphocytes, in Fnip1 À/À versus WT pre-B cells ( Figure 4A ). In addition, essential mitochondrial genes including Ucp3 (uncoupling protein 3), Atp5g1 (mitochondrial ATPase, C1 subunit), and mt-Cytb (Cytochrome b) were also significantly increased in pre-B cells from Fnip1 À/À mice relative to WT mice ( Figure 4A ). Flow cytometry and transmission electron microscopy (EM) analyses further revealed that Fnip1 À/À B cell progenitors exhibited increased labeling with the mitochondrial dye MitoTracker green relative to WT B cell progenitors ( Figure 4B ) and contained significantly increased numbers of mitochondria ( Figure 4C ). Fnip1 À/À B cell progenitors took up the fluorescent deoxyglucose analog 2-NBDG more effectively than did WT pre-B cells in response to IL-7 ( Figure 4D ). These results confirmed that the upregulated AMPK and PGC-1a gene signature correlates with increased AMPK and PGC1a function in Fnip1-null pre-B cells. To determine whether the upregulated mTOR gene signature correlated with increased cell growth, we examined mTOR activation and cell size by flow cytometry. We found that relative to WT pre-B cells, Fnip1 À/À pre-B cells exhibited increased intracellular phospho-S6 ribosomal protein (pS6R) ( Figure 4E ), which is a downstream mediator of mTOR signaling that stimulates ribosome biogenesis and translation and are significantly larger in size relative to WT pre-B cells and Rag2 À/À pro-B cells ( Figure 4F ).
These results collectively suggest that loss of Fnip1 results in parallel increases in catabolic metabolism and mTOR-mediated anabolic metabolism, two normally antagonistic energyregulating processes that typically occur separately.
Fnip1 Controls the Ability of AMPK to Inhibit mTOR-Mediated Cell Growth
Although the cellular and molecular functions of Fnip1 are unknown, both Fnip1 (Baba et al., 2006) and Fnip2 (Hasumi et al., 2008; Takagi et al., 2008) have been shown to interact with all three subunits (a, b, g) of AMPK. To examine how Fnip1 might interact with pre-BCR signaling and metabolism, we assessed the presence and activation of known pre-BCR See also Figure S2 . See also Figure S4 .
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Immunity 36, 1-13, May 25, 2012 ª2012 Elsevier Inc. 7 signaling molecules after stimulation with a-Igb-coated beads (Nagata et al., 1997) . Crosslinking of Igb on purified B cell progenitors from Fnip1 À/À and Rag2 À/À control mice resulted in equivalent increases in total tyrosine ( Figure 5A ) or serine/ threonine phosphorylated proteins including Syk, Blnk (Slp65), Btk, Akt, Erk, and IKKa/b ( Figure S5A ), suggesting that pre-BCR signaling is activated normally in the absence of Fnip1. Figure 4E ). AMPK appeared to phosphorylate (and presumably inhibit) the mTOR partner Raptor normally in the absence of Fnip1 (Gwinn et al., 2008) . Akt (a positive regulator of mTOR) was phosphorylated normally at the Thr308 and Ser473 activation sites (Sengupta et al., 2010) Figure 6B and data not shown). Furthermore, removal of essential amino acids (EAA) significantly inhibited the development of Fnip1 À/À IgM + B cells, which could be rescued in a dose-dependent manner by the addition of EAAs ( Figure 6C ). Administration of oligomycin, which blocks ATP synthase and oxidative phosphorylation, also inhibited the emergence of Fnip1 À/À IgM + B cells at concentrations that do not affect the development of WT IgM + B cells ( Figure 6D ).
To examine why Fnip1 À/À B cells might be in metabolic deficit, we analyzed pre-B cell metabolism on FACS-sorted pre-B cells with the Seahorse Extracellular Flux Analyzer. Fnip1 À/À pre-B cells have decreased basal oxygen consumption rate (OCR), which is a measure of oxidative phosphorylation (OXPHOS) (Figure 6E ). OCR and extracellular acidification rate (ECAR), which is a measure of glycolysis, could be restored to a hypermetabolic state in Fnip1 À/À pre-B cells by the addition of IL-7, which 
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Fnip1 Is Essential for B Cell Development stimulates glucose uptake ( Figure 4D ) and restores energy balance (Figures 6E; Rathmell et al., 2001) . Fnip1 À/À pre-B cells also exhibited increased sensitivity to 2-deoxyglucose (glycolysis inhibitor) and etoxomir (fatty acid oxidation inhibitor) (Figure 6F ), which correlated with decreased basal ATP levels relative to WT pre-B cells ( Figure 6G ).
To examine whether increased PPARg or dysregulated mTOR ( Figure S5D IgM expression in Fnip1 À/À pre-B cells ( Figure S7B ), suggesting that increased expression of PPARg ( Figure 4A ) may reflect an attempt to maintain energy balance in response to dysregulated mTOR. Likewise, activation of PPARg in WT pre-B cells with the agonist troglitazone did not inhibit pre-B to immature B cell development, although the cells exhibited increased nonspecific apoptosis ( Figure S7C ). Injection of Fnip1 À/À mice with the mTORC1-inhibitor rapamycin also failed to rescue B cell development in vivo. However, delivery of a combination of rapamcyin and IL-7 (which increases glucose uptake) were sufficient to rescue the emergence of IgM + cells in Fnip1 À/À mice after 2 weeks ( Figure S7D ). These results collectively suggest that loss of Fnip1 results in excessive mTOR-mediated metabolite consumption, increased nutrient demand, impaired OXPHOS, and IL-7 ''addiction,'' which prevent the development of pre-B cells in response to nutrient stress and pre-BCR crosslinking. (Adams et al., 1985) . As a control, we also bred Fnip1 À/À mice to Ighm tm1Cgn (also known as mMT) mice, which are also arrested in B cell development at the pre-B cell stage as a result of targeted disruption of the transmembrane portion of Igm (Figure 7A ; Kitamura and Rajewsky, 1992) . Em-MycFnip1
À/+ or +/+ mice exhibited nearly identical Kaplan-Meier lymphoma-free curves ( Figure 7B ), indicating that loss of one allele of Fnip1 has no effect on pre-B cell transformation by c-Myc. Targeted disruption of Igm resulted in accelerated B cell transformation by c-Myc (Em-MycmMT), probably because B cell development is arrested at an IL-7-responsive pre-B cell stage (Herzog et al., 2009) . In contrast, despite a similar block in B cell development ( Figure 7A 
DISCUSSION
Resting B lymphocytes respond to foreign pathogens by rapidly shifting from a quiescent state to a metabolically activated phenotype, characterized by massive increases in macromolecular synthesis necessary for cell growth, division, and eventually Ig synthesis (see Rathmell, 2004, for review also exhibit impaired B cell development at the large pre-B cell stage (see Herzog et al., 2009 , for review), we find that these pathways (as well as important transcriptional mediators) are expressed or activated normally in Fnip1 À/À pre-B cells after a-Igb crosslinking. A second unique feature of Fnip1 is that loss of Fnip1 blocks pre-BCR-induced differentiation, whereas pre-BCR-induced proliferation (synergistic with IL-7) and allelic exclusion of the IgH chain loci remain intact. This is in contrast to disruption of the membrane portion of IgH, Iga and Igb, or Syk and Zap70, which result in blocked proliferation, differentiation, and allelic exclusion (Kurosaki et al., 2010) . A third unique feature is that loss of Fnip1 potently inhibits transformation and/or survival by Myc, whereas disruption of another pre-BCR signaling molecule Igm (which also blocks B cell development at the pre-B cell stage) results in significantly accelerated Mycinduced transformation. These results collectively highlight that Fnip1 functions in a distinct manner from most of the known pre-BCR signaling molecules.
Fnip1 was cloned based on its interactions with Folliculin and AMPK in kidney cells (Baba et al., 2006) and was subsequently shown to interact with Fnip2. Here, we find that AMPK is activated normally in pre-B cells from Fnip1 À/À mice relative to WT mice. In addition, we find increased expression of essential AMPK-induced mitochondrial metabolic genes and increased glucose uptake and mitochondrial biogenesis in Fnip1 À/À pre-B cells. However, whereas AMPK activation in WT pre-B cells shuts down mTOR-mediated anabolic (ATP and bioprecursorconsuming) growth (Gwinn et al., 2008) , AMPK fails to inhibit mTOR-mediated growth in Fnip1 À/À pre-B cells, which correlates with decreased energy balance (decreased ATP) and increased sensitivity to apoptosis after pre-BCR activation, nutrient or IL-7 deprivation, or oncogene activation. These results, combined with previous studies by Baba et al. (2006) in HEK cells, suggest that Fnip1 acts downstream of AMPK to help maintain ''metabolic homeostasis'' in B lineage cells during metabolic stress (see Figure S5D for model). Recent studies indicate that disruption of AMPK-activator LKB also inhibits pre-TCR-mediated T cell development (Tamá s et al., 2010) , and disruption of LKB1 in hematopoietic stem cells results in dysregulated mTOR, increased cell growth, and decreased survival of differentiated hematopoietic cells (Gan et al., 2010; Gurumurthy et al., 2010; Nakada et al., 2010) . Similar to Fnip1 deficiency, hematopoietic cell development is not rescued by rapamycin alone, indicating that Fnip1 and LKB1 may function in both mTORC1-dependent and -independent manners. Indeed, B cell development in Fnip1 À/À mice can only be partially rescued by a combination of rapamycin (which inhibits mTORC1) and IL-7 (which stimulates glucose uptake and OXPHOS). Whereas both Fnip1 and Fnip2 are expressed during B cell development in WT mice, only Fnip2 is significantly regulated with expression peaking in immature B cells. In addition, Fnip2 mRNA levels increase in Fnip1-null pre-B cells (data not shown). These results suggest that Fnip1 and Fnip2 may only be active as heterodimers, which would explain why Fnip2 does not compensate for the absence of Fnip1. Targeted disruption of the Fnip2 gene in mice should shed light on this issue.
An important distinction between Fnip1-null pre-B cells, which exhibit increased mTOR activity, and other human diseases whereby mTOR is dysregulated is the absence of benign or malignant overgrowth. For example, mutations in LKB1, PTEN, FLCN, and TSC1/2 result in deregulated mTOR and overgrowth (hamartoma) syndromes or cancer in humans (see Shackelford and Shaw, 2009, for review) . In addition, loss-of-function mutations in the PPKAG2 gene encoding the a subunit of AMPK result in familial cardiac hypertrophy and Wolf-Parkinson's-White syndrome, overgrowth diseases characterized by cardiac hypertrophy and arrhythmias resulting from dysregulated mTOR (Arad et al., 2007) . We find that loss of Fnip1 also results in cardiac hypertrophy and excessive growth of pre-B cells characterized by dysregulated mTOR. However, we have not observed transformation of any cell types including pre-B cells, and we find that loss of Fnip1 inhibits pre-B cell lymphomagenesis by the c-Myc oncogene, which potently drives transformation in part by increasing the metabolic capacity of cancer cells (see Dang et al., 2009, for review) . Thus, our results suggest the existence of a ''metabolic checkpoint'' during B cell development, which inhibits the maturation and survival of pre-B cells that are ''metabolically insufficient,'' either because of mutations that disrupt energy-or bioprecursor-generating pathways and/ or because of excessive energy or bioprecursor consumption. Inhibition of Fnip1 could provide a novel mechanism to limit the fuel necessary to support cancer cell metabolism (Vander Heiden et al., 2009) , thus selectively sensitizing highly metabolic cancer cells for apoptosis in response to chemotherapy or metabolic stress.
